Ladenburg Thalmann Rates Alterity Therapeutics (ATHE) buy
Ladenburg Thalmann raises ATHE's rating to buy with a $10 price target, a 126.76% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Ladenburg Thalmann rated Alterity Therapeutics Limited ($ATHE) "buy" with a $10 price target on June 16, 2026.
Since the rating, $ATHE is up 6.7% after 1 week, up 9.5% after 1 month and down 43.7% to date (from the $4.65 close on Jun 16, 2026).
ATHE
Alterity Therapeutics Limited
Key Points
- On June 16, 2026, Ladenburg Thalmann raised its rating on ATHE to buy, setting a $10 price target.
- Ladenburg Thalmann's $10 price target implies 126.76% upside from Alterity Therapeutics Limited's ($ATHE) current $4.41 share price.
- Shares of ATHE traded near $4.41 at the time of the rating change.
- Morgan Stanley reduced its ATHE holdings by 5,300 shares, while Citadel Advisors increased its position by 3,266 shares.
Get $ATHE trade alerts by text
We text you when insiders, Congress or big funds trade $ATHE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alterity Therapeutics Limited alert may contain errors. Disclosures
On June 16, 2026, Ladenburg Thalmann raised its rating on ATHE to a buy, setting a price target of $10. This change comes as the stock was trading around $4.41.
Other Institutional Activity in ATHE
Among ATHE's institutional investors, Morgan Stanley trimmed its holdings by 5,300 shares, leaving it with 58,382 shares valued at approximately $203,170. Meanwhile, Citadel Advisors LLC increased its position by 3,266 shares, bringing its total to 20,077 shares worth about $71,474. Twin Lakes Capital Management, HB Wealth Management, and Greenleaf Trust all maintained their positions without any change.
Analysts Set New Price Targets
On June 16, 2026, Ladenburg Thalmann assumed coverage of ATHE with a buy rating and a $10 price target. Previously, on January 30, 2025, Maxim Group maintained its buy rating with a $12 target, while on December 19, 2024, it initiated coverage with a buy rating and an $8 target.
About ATHE
ATHE operates in the pharmaceutical industry, focusing on the development of innovative therapies. The company is engaged in researching and bringing to market treatments that address unmet medical needs. ATHE is committed to advancing its pipeline and delivering new solutions to patients worldwide.
Bottom Line
The latest rating adjustment by Ladenburg Thalmann suggests a positive outlook for ATHE, with a significant upside implied by the new price target. Investors often track such analyst updates for insights into potential stock performance. As always, it's important to remember that analyst ratings are one of many factors investors consider when evaluating a stock.
$ATHE price target
Alterity Therapeutics Limited daily closes and this analyst's $10 target. Not advice.
Related Filing Alerts
Source: Ladenburg Thalmann's rating change on $ATHE (Jun 16, 2026). Written by software, not financial advice. How we make alerts